Clinical Trial Update: A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating intravesical SHR-1501 combined with BCG versus investigator-selected chemotherapy in patients with BCG-unresponsive non-muscle invasive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• SHR-1501

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: NMIBC | Phase 3 | Status: NOT_YET_RECRUITING